Trials Sponsors Conditions Drugs Pricing

Conditions

Coronary Artery Disease

Keywords

percutaeneous coronary interventiondual antiplatelet therapygastrointestinal protection

Outcome Measures

Primary Outcomes (1)

Major GI bleeding
Major GI bleeding requiring transfusion
at 1 year

Secondary Outcomes (5)

Clinically relevant GI bleeding
At 1 year
Major adverse cardiac event
At 1 year
Cardiovascular death
At 1 year
Myocardial infarction
At 1 year
Repeat revascularization
At 1 year

Study Arms (2)

Routine use of P-CAB

All-comer patients with P-CAB

Drug: Routine use of P-CAB on DAPT

Guideline-directed GI protection strategy

Use of PPI or not according to GI bleeding risk

Drug: Guideline Directed Medical Therapy

Interventions

Routine use of P-CAB on DAPTDrug

This group received P-CAB with DAPT after PCI.

Routine use of P-CAB

Guideline Directed Medical TherapyDrug

This group received PPI or not with DAPT after PCI according to GI bleeding risk.

Guideline-directed GI protection strategy

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

patients with coronary artery disease who underwent PCI

You may qualify if:

Patients who underwent PCI

Sponsors & Collaborators

Samsung Medical Center
Otherlead

Study Sites (1)

Samsung Medical Center

Seoul, 06351, South Korea

RECRUITING

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

KI HONG CHOI, MD, PhD
Samsung Medical Center
PRINCIPAL INVESTIGATOR

Central Study Contacts

Ki Hong Choi, MD, PhD

CONTACT

82-2-3410-3419 cardiokh@gmail.com

Danbee Kang, PhD

CONTACT

82-2-2148-7197

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Associate Professor

Study Record Dates

First Submitted

July 6, 2025

First Posted

July 16, 2025

Study Start

October 22, 2024

Actual (reported)

Primary Completion

December 31, 2025

Estimated (date passed)

Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (2)

Routine use of P-CAB

Guideline-directed GI protection strategy

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (2)

Routine use of P-CAB

Guideline-directed GI protection strategy

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations